187 related articles for article (PubMed ID: 36606718)
21. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
22. Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation.
Epperla N; Hamadani M; Ahn KW; He F; Kodali D; Kleman A; Hari PN; Pasquini M; Fenske TS; Craig MD; Kanate AS; Bachanova V
Biol Blood Marrow Transplant; 2018 May; 24(5):983-988. PubMed ID: 29410340
[TBL] [Abstract][Full Text] [Related]
23. Impact of risk scores in outcome of patients with myeloid neoplasms after allogeneic stem cell transplant.
Fernández-Caballero M; Jiménez Lorenzo MJ; Morgades de la Fe M; Ferrà Coll C; Vives Polo S; Abril Sabater L; Navarro Ferrando JT; Ribera Santasusana JM
Med Clin (Barc); 2022 May; 158(10):451-457. PubMed ID: 34404519
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.
Maymani H; Lin P; Saliba RM; Popat U; Bashir Q; Shah N; Patel K; Parmar S; Kebriaei P; Hosing C; Ciurea S; Andersson B; Shpall E; Champlin R; Srour SA; Qazilbash MH
Biol Blood Marrow Transplant; 2019 May; 25(5):1039-1044. PubMed ID: 30639822
[TBL] [Abstract][Full Text] [Related]
25. Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation.
Epperla N; Ahn KW; Khanal M; Litovich C; Ahmed S; Ghosh N; Fenske TS; Kharfan-Dabaja MA; Sureda A; Hamadani M
Transplant Cell Ther; 2021 Jan; 27(1):58-66. PubMed ID: 32956819
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
Sharma P; Shinde SS; Damlaj M; Hefazi Rorghabeh M; Hashmi SK; Litzow MR; Hogan WJ; Gangat N; Elliott MA; Al-Kali A; Tefferi A; Patnaik MM
Leuk Lymphoma; 2017 Apr; 58(4):872-881. PubMed ID: 27687869
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years.
Bazarbachi A; Schmid C; Labopin M; Beelen D; Wolfgang Blau I; Potter V; Niittyvuopio R; Socié G; Blaise D; Sanz J; Ciceri F; Abou Dalle I; Spyridonidis A; Bug G; Esteve J; Savani BN; Nagler A; Mohty M
Clin Cancer Res; 2020 Dec; 26(24):6475-6482. PubMed ID: 32988970
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
[TBL] [Abstract][Full Text] [Related]
29. Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
Connor MP; Loren AW; Hexner EO; Martin ME; Gill SI; Luger SM; Mangan JK; Perl AE; McCurdy SR; Pratz KW; Timlin C; Freyer CW; Carulli A; Catania C; Smith J; Hollander L; Zebrowski AM; Stadtmauer EA; Porter DL; Frey NV
Transplant Cell Ther; 2023 Feb; 29(2):113-118. PubMed ID: 36336258
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of a Second Allogeneic Hematopoietic Cell Transplant in Relapsed Acute Myeloid Leukemia: Results of a Systematic Review and Meta-Analysis.
Kharfan-Dabaja MA; Reljic T; Yassine F; Nishihori T; Kumar A; Tawk MM; Keller K; Ayala E; Savani B; Mohty M; Aljurf M; Saber W
Transplant Cell Ther; 2022 Nov; 28(11):767.e1-767.e11. PubMed ID: 35970301
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis.
Epperla N; Ahn KW; Litovich C; Ahmed S; Battiwalla M; Cohen JB; Dahi P; Farhadfar N; Farooq U; Freytes CO; Ghosh N; Haverkos B; Herrera A; Hertzberg M; Hildebrandt G; Inwards D; Kharfan-Dabaja MA; Khimani F; Lazarus H; Lazaryan A; Lekakis L; Murthy H; Nathan S; Nishihori T; Pawarode A; Prestidge T; Ramakrishnan P; Rezvani AR; Romee R; Shah NN; Sureda A; Fenske TS; Hamadani M
J Hematol Oncol; 2019 Jan; 12(1):6. PubMed ID: 30630534
[TBL] [Abstract][Full Text] [Related]
32. Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse.
Kharfan-Dabaja MA; Labopin M; Polge E; Nishihori T; Bazarbachi A; Finke J; Stadler M; Ehninger G; Lioure B; Schaap N; Afanasyev B; Yeshurun M; Isaksson C; Maertens J; Chalandon Y; Schmid C; Nagler A; Mohty M
JAMA Oncol; 2018 Sep; 4(9):1245-1253. PubMed ID: 30003233
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Aladağ E; Demiroğlu H; Büyükaşık Y; Göker H
Turk J Haematol; 2021 Jun; 38(2):138-144. PubMed ID: 32539316
[TBL] [Abstract][Full Text] [Related]
34. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients.
Boyiadzis M; Zhang MJ; Chen K; Abdel-Azim H; Abid MB; Aljurf M; Bacher U; Badar T; Badawy SM; Battiwalla M; Bejanyan N; Bhatt VR; Brown VI; Castillo P; Cerny J; Copelan EA; Craddock C; Dholaria B; Perez MAD; Ebens CL; Gale RP; Ganguly S; Gowda L; Grunwald MR; Hashmi S; Hildebrandt GC; Iqbal M; Jamy O; Kharfan-Dabaja MA; Khera N; Lazarus HM; Lin R; Modi D; Nathan S; Nishihori T; Patel SS; Pawarode A; Saber W; Sharma A; Solh M; Wagner JL; Wang T; Williams KM; Winestone LE; Wirk B; Zeidan A; Hourigan CS; Litzow M; Kebriaei P; de Lima M; Page K; Weisdorf DJ
Leukemia; 2023 May; 37(5):1006-1017. PubMed ID: 36310182
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
Domingo-Domenech E; Duarte RF; Boumedil A; Onida F; Gabriel I; Finel H; Arcese W; Browne P; Beelen D; Kobbe G; Veelken H; Arranz R; Greinix H; Lenhoff S; Poiré X; Ribera JM; Thompson J; Zuckerman T; Mufti GJ; Cortelezzi A; Olavarria E; Dreger P; Sureda A; Montoto S
Bone Marrow Transplant; 2021 Jun; 56(6):1391-1401. PubMed ID: 33420392
[TBL] [Abstract][Full Text] [Related]
36. Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.
Salit RB; Deeg HJ
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1023-35. PubMed ID: 25459177
[TBL] [Abstract][Full Text] [Related]
37. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
Michelis FV; Gupta V; Zhang MJ; Wang HL; Aljurf M; Bacher U; Beitinjaneh A; Chen YB; DeFilipp Z; Gale RP; Kebriaei P; Kharfan-Dabaja M; Lazarus HM; Nishihori T; Olsson RF; Oran B; Rashidi A; Rizzieri DA; Tallman MS; de Lima M; Khoury HJ; Sandmaier BM; Weisdorf D; Saber W;
Cancer; 2017 Jun; 123(11):2035-2042. PubMed ID: 28117898
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT.
Hernández-Boluda JC; Pereira A; Zinger N; Gras L; Martino R; Nikolousis E; Finke J; Chinea A; Rambaldi A; Robin M; Saccardi R; Natale A; Snowden JA; Tsirigotis P; Vallejo C; Wulf G; Xicoy B; Russo D; Maertens J; Daguindau E; Lenhoff S; Hayden P; Czerw T; McLornan DP; Yakoub-Agha I
Bone Marrow Transplant; 2022 Mar; 57(3):416-422. PubMed ID: 35066569
[TBL] [Abstract][Full Text] [Related]
39. Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).
Cahu X; Chevallier P; Clavert A; Suarez F; Michallet M; Vincent L; Vigouroux S; Blaise D; Mariette C; Bilger K; Robin M; Yakoub-Agha I; Peffault de Latour R; Mohty M
Bone Marrow Transplant; 2014 Jun; 49(6):756-60. PubMed ID: 24614840
[TBL] [Abstract][Full Text] [Related]
40. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
